XHKG
8225
Market cap9mUSD
Oct 09, Last price
0.08HKD
1D
9.72%
1Q
-16.84%
Jan 2017
-60.30%
IPO
-70.48%
Name
China Health Group Inc
Chart & performance
P/E
—
P/S
2.41
EPS
—
Div yield, %
—
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
-19.65%
Revenues
28m
+5.18%
Net income
-15m
L+0.38%
CFO
9m
-12.19%
Dividend
Apr 07, 20040.005 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
China Health Group Inc., an investment holding company, researches and develops drugs, bio drugs, natural drugs, and synthetic drugs in the People’s Republic of China. The company offers contracted pharmaceutical development and clinical research, and post market; and post launch market research, medical science, and medical market services. It also provides hospital management, clinical research and promotion, rehabilitation tourism, and specialty hospital services, as well as Wanquan cloud health services. In addition, the company offers pharmacodynamics and clinical research of drugs. China Health Group Inc. was formerly known as Venturepharm Laboratories Limited and changed its name to China Health Group Inc. in January 2015. The company was founded in 1998 and is headquartered in Beijing, China.
Key people
Xia Guo
Executive Chairman of the Board, Chief Executive Officer, Joint Chief Technology Officer, Managing Director · since 2015
Liang Li
Financial Director · since 2016
Tuo Jin
Joint Chief Technology Officer
Xue Mei Song
Compliance Officer, Executive Director · since 2015
Tarun Gupta
Co-Head - Business Development Department, International Division
Albert Qin
Chief Medical Officer · since 2016
Company Secretary · since 2020
Yan Xing
Joint Company Secretary · since 2019
Michael Su
Non-Executive Director · since 2016
Zhen Ling
Non-Executive Independent Director · since 2018
Bin Hui Ni
Independent Non-Executive Director · since 2015
Rui Qiu
Non-Executive Independent Director · since 2018
Legal address
c/o Offshore Incorporations (Cayman) Limited
4th Floor Willow House
Cricket Square
PO-Box 2804
Grand Cayman KY1-1112
KY
4th Floor Willow House
Cricket Square
PO-Box 2804
Grand Cayman KY1-1112
KY
Headquarters
4th Floor Willow House
Cricket Square
PO-Box 2804
Grand Cayman KY1-1112
KY
Cricket Square
PO-Box 2804
Grand Cayman KY1-1112
KY
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||